Jun 22, 2020
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 27, 2020
OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO(TM) and Its Electroporation Gene Delivery System
May 21, 2020
OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
Apr 21, 2020
OncoSec Presents Pre-Clinical Data from Its Visceral Lesion Applicator (VLA) and APOLLO Feasibility Study Demonstrating TAVO(TM) Can Be Safely Delivered and Electroporated in Liver at the Online Society of Interventional Radiology Annual Meeting
Apr 06, 2020
OncoSec Collaborates with Providence Cancer Institute to Conduct First-in-Human Trial of OncoSec's CORVax12, an Investigational Vaccine to Prevent COVID-19, Combining an Enhanced "Spike" DNA Sequence and TAVO(TM)
Mar 24, 2020
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T(TM)) Therapies
Mar 17, 2020
PharmaJet Received Multi-Year, Multi-Million Dollar Award to Support Next-Generation Needle-Free Delivery Devices
Mar 10, 2020
Global Transfection Technologies Market Analysis, 2020-2025 - Increasing R&D in the Field of Cell-Based Therapies
Feb 04, 2020
Clinical Cancer Research highlights OncoSec's Merkel Cell Carcinoma Clinical Study on the Cover of its February Issue
Feb 03, 2020
OncoSec's Visceral Lesion Applicator (VLA) Electroporation Device Demonstrates Targeted Entry and Deployment in Both Lung and Liver in Data Presented at the Society of Interventional Oncology Annual Meeting
Jan 30, 2020
FARAPULSE Extensively Showcased at Leading AF Symposium
Jan 28, 2020
The Global Electroporation Instruments Market is expected to grow by USD 72.67 mn during 2020-2024, progressing at a CAGR of 7% during the forecast period
Aug 30, 2019
Using Precision Engineering to Streamline Manufacturing of Next-Generation Cellular Therapies
Jun 17, 2019
OncoSec Announces Research Collaboration with Roswell Park Comprehensive Cancer Center Using Cutting-Edge Intravital Microscopy (IVM), TAVO-PLUS and APOLLO(TM) Electroporation Generator
May 29, 2019
MaxCyte CEO Doug Doerfler to Present at 2019 BIO International Convention
May 08, 2019
MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA(TM) Platform
Apr 17, 2019
OncoSec Announces Collaborative Research Agreement in HER2+ Breast Cancer Evaluating the Use of TAVO(TM) in Combination with Plasmid DNA Vaccines with a World Leading Academic Medical Center
Apr 10, 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
Apr 08, 2019
MaxCyte® Launches ExPERT(TM) Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies
Nov 21, 2018
MaxCyte to Present at Piper Jaffray 30th Annual Healthcare Conference